IRVINE, Calif.–(BUSINESS WIRE)–Balt USA, LLC announces today it has obtained CE mark for the Titan aspiration catheter. The Titan catheter line consists of a highly navigable, large bore (.070”) aspiration catheter and a smaller bore (.036”) catheter for navigation and support. Obtaining the CE mark for Titan* enhances the Balt stroke […]
Other News
Ra Medical Systems Reports First Quarter 2019 Financial Results
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2019 and provides a business update. Recent Operational Highlights Submitted an Investigational Device Exemption (IDE) to the […]
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under […]
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days. The Impella 5.0 and the Impella LD are forward flow heart pumps […]
FDA Grants First Ever Clearance For Six-Lead Personal ECG Device
MOUNTAIN VIEW, Calif., May 13, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared consumer electrocardiogram technology (ECG), today announced its third FDA clearance in three months, making KardiaMobile 6L the world’s first available six-lead personal ECG device. This highly anticipated clearance gives patients and their physicians an even more detailed view into patients’ […]
MyoKardia Reports First Quarter 2019 Financial Resul
Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment […]
NEW STUDIES HIGHLIGHT UNDERUSE OF IMPLANTABLE CARDIAC DEVICES
DUBLIN and SAN FRANCISCO – May 10, 2019 – Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), often do not receive needed therapy. The findings underscore gender and race treatment disparities, as well as a […]
Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of a new scientific article in the […]
CardioFocus Announces Impressive Results From Pivotal Confirmatory Study With The Breakthrough HeartLight® X3 System
MARLBOROUGH, Mass., May 10, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment of AFib. The results, which demonstrated superior procedural times and impressive procedural […]
BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance
– As reported, revenues of $4.195 billion decreased 0.6 percent. – On a comparable, currency-neutral basis, revenues increased 3.4 percent. – As reported, diluted earnings per share of $(0.07) increased 63.2 percent. – As adjusted, diluted earnings per share of $2.59 decreased 2.3 percent, and increased 7.2 percent on a […]



